Skip to main content

Table 1 Urinary estrogen concentrations associated with benign tumors and malignant Papillary Thyroid Carcinomas (PTCs) in the postmenopausal women

From: Comparison of metabolic ratios of urinary estrogens between benign and malignant thyroid tumors in postmenopausal women

Compounds (trivial name)

Benign tumor (a) (n = 9)

Malignant PTCs

 

P-value2

Stage I (b) (n = 11)

Stage III/IV (C) (n = 7)

P-value1

a vs. b

a vs. c

b vs. c

Estrone (E1)

12.1 ± 11.3

2.9 ± 2.3

5.0 ± 6.5

0.053

0.020

0.091

0.791

17β-estradiol (E2)

0.8 ± 0.6

0.4 ± 0.2

1.1 ± 1.3

0.416

   

Estriol (E3)

1.7 ± 1.7

1.9 ± 1.7

6.2 ± 6.7

0.146

   

2-hydroxyestrone (2-OH-E1)

2.2 ± 3.5

0.3 ± 0.3

0.7 ± 1.2

0.073

   

2-hydroxy-17β-estradiol (2-OH-E2)

0.5 ± 0.4

0.1 ± 0.1

0.3 ± 0.2

0.052

0.031

0.536

0.085

4-hydroxyestrone (4-OH-E1)

0.6 ± 0.5

0.3 ± 0.3

0.4 ± 0.4

0.558

   

4-hydroxy-17β-estradiol (4-OH-E2)

0.5 ± 0.4

0.1 ± 0.1

0.2 ± 0.1

0.182

   

2-methoxyestrone (2-MeO-E1)

1.6 ± 1.7

0.5 ± 0.4

0.6 ± 0.6

0.108

   

2-methoxy-17β-estradiol (2-MeO-E2)

1.4 ± 1.1

0.4 ± 0.3

0.6 ± 0.4

0.034

0.012

0.114

0.285

4-methoxyestrone (4-MeO-E1)

0.6 ± 0.8

0.1 ± 0.1

0.2 ± 0.4

0.011

0.004

0.174

0.179

4-methoxy-17β-estradiol (4-MeO-E2)

0.3 ± 0.7

0.1 ± 0.1

0.2 ± 0.2

0.104

   

17-epiestriol (17-epi-E3)

0.3 ± 0.3

0.1 ± 0.1

0.1 ± 0.1

0.029

0.016

0.142

0.425

16-epiestriol (16-epi-E3)

0.7 ± 0.9

0.3 ± 0.2

0.9 ± 1.0

0.589

   

16α-hydroxyestrone (16α-OH-E1)

0.9 ± 0.7

0.6 ± 0.6

0.8 ± 0.8

0.462

   

16-keto-17β-estradiol (16-keto-E2)

0.7 ± 0.9

0.6 ± 0.6

0.7 ± 1.0

0.803

   
  1. Concentrations are expressed as ng/mg of creatinine (mean ± SD).
  2. Statistical significance was determined by a nonparametric 1Kruskal-Wallis and 2Mann-Whitney U test to evaluate possible differences in the diagnostic factors.
  3. The significant estrogens with P < 0.05 in a Kruskal-Wallis test were then compared with the Mann–Whitney U test results between 2 groups, including benign versus stage I PTC (a vs. b), benign versus stage III/IV PTC (a vs. c), and stage I versus stage III/IV PTC (b vs. c). A Bonferroni correction was applied to the post hoc analysis of the between-group comparisons performed for each variable and to set the significance level at 0.017.